The average lifetime risk of breast cancer for a woman in the United States is one in eight ([@bib38]). Women who have a strong family history of breast or ovarian cancer, cancer-predisposing *BRCA* mutations, or other risk factors such as prior thoracic radiation at an early age (e.g., for the treatment of Hodgkin\'s disease) have an increased risk of developing the disease. For women with an average breast cancer risk, several major cancer societies recommend screening using various combinations of mammography and clinical breast examination (CBE). For women at an increased risk for breast cancer, it has been suggested that further extensions to general screening guidelines such as more frequent examinations, earlier starting ages of screening (e.g., age 30), or additional screening modalities, may be beneficial ([@bib49]). For example, the National Institute for Health and Care Excellence in the United Kingdom suggests that women with high risk for breast cancer should have mammography every year beginning at age 40, and earlier if they are known to carry certain gene mutations ([@bib54]).

One commonly discussed extension is to augment screening mammography with magnetic resonance imaging (MRI). Although MRI has been found to have a higher sensitivity than screening mammography among younger women with dense breasts, reports of its specificity have been lower in high-risk women ([@bib26]; [@bib24]; [@bib55]; [@bib27]; [@bib25]), resulting in a higher rate of false-positive results. In addition, MRI is expensive and its administration and interpretation require more highly trained personnel. Decision makers who are interested in integrating MRI into the screening programme for women at high risk for breast cancer must weigh the potential survival benefit from MRI against its much higher costs and increased false-positive results, which lead to unnecessary testing procedures and a reduction in health utility. Thus it is important to assess the clinical as well as economic implications of adding MRI to current screening programmes for high-risk women so as to identify cost-effective screening strategies involving MRI.

Although there are cost-effectiveness studies of breast MRI screening for women at increased risk for breast cancer, the vast majority of these studies have focused on adding MRI to screening mammography for *BRCA1* or *BRCA2* carriers ([@bib37]; [@bib14]; [@bib18]; [@bib34]). Findings from these studies have contributed to the development of screening guidelines for women with these mutations. It is now well accepted that annual screening with MRI should be recommended for women with *BRCA1* or *BRCA2* gene mutations. For other women at high risk for breast cancer, there is currently no consensus on how MRI should be incorporated into clinical practice. Few existing guidelines for MRI in breast cancer screening specifically discuss the level of lifetime risk for breast cancer at which MRI should be recommended. One exception is the MRI screening guideline from the American Cancer Society (ACS; [@bib4]), which recommends an MRI and a mammogram every year for women with a lifetime risk of 20--25% or greater ([@bib42]). However, it is unclear how to integrate MRI into the current screening programmes, which typically consist of mammography and CBE. It is also unclear if at this level of lifetime risk the additional benefit from annual MRI screening outweighs the additional costs, or whether a longer screening interval for MRI (e.g. 2 years) is more cost-effective.

Approximately, 10% of breast cancers are caused by *BRCA1* and *BRCA2* mutations ([@bib1]); therefore, findings from cost-effectiveness studies focusing on women carrying these mutations cannot be generalised to the evaluation of the ACS guideline for MRI screening, as the level of lifetime risk underlying the ACS recommendation targets a much larger group of women at high risk of breast cancer. Other cost-effectiveness studies that did not focus exclusively on *BRCA1* or *BRCA2* mutation carriers were limited by the types of screening strategies explored in their comparisons, such as the comparison between MRI-only *vs* mammography-only in [@bib29], or MRI with *vs* without X-ray mammography in [@bib50]. Neither considered CBE. A recent cost-effectiveness analysis by [@bib41] considered augmenting the current screening practice in the Dutch nationwide screening programme (i.e., biennial mammography from 50 to 75 years) with several screening strategies among women aged 35--50 with familial risk for breast cancer, including the screening strategy of CBE every 6 months combined with annual mammography and MRI explored in a prospective MRI screening study. However, the model in their study was designed to explore what augmentation to the existing screening programme was most cost-effective, instead of investigating *how* MRI should be incorporated into current practice for high-risk women, with or without mammography plus CBE.

If mammography screening is insufficient for these women and the higher sensitivity of MRI could offer a better alternative, what is the best way to integrate MRI into current clinical practice given its much higher cost and also lower specificity? There are many ways to incorporate MRI into current screening practice of mammography screening combined with CBE. For high-risk women, clinicians may be reluctant to recommend a screening interval of \>1 year. Given this requirement, several screening strategies involving MRI are possible, such as replacing annual mammography screening plus CBE with annual MRI, alternating mammography plus CBE with MRI every year, performing MRI immediately following annual mammography plus CBE, and others. To answer the above question, we employ a microsimulation model to investigate the cost-effectiveness of various strategies of adding MRI to mammography and CBE (or using MRI alone) for a cohort of women with high risk for breast cancer. Instead of restricting our cohort to a small subset of high-risk women who are *BRCA1* or *BRCA2* mutation carriers, we chose our study cohort to be consistent with the population targeted in the ACS guidelines for high-risk women: women aged 30 and above with a 25% lifetime risk or greater of developing breast cancer. This approach allows us to directly assess the cost-effectiveness of screening strategies recommended in the ACS guidelines of MRI screening. We assessed 12 practical screening strategies with different intervals and cessation age of MRI in combinations of biannual, annual, or biennial examinations of mammography and CBE, or none. Together, these combinations offer the opportunity for a comprehensive assessment of screening strategies that add MRI to standard screening programmes using mammography and CBE alone.

Materials and methods
=====================

Overview
--------

Using Monte Carlo simulation programmed in R (Vienna, Austria; <http://www.R-project.org>), we generated the natural histories of a large cohort of women at high risk for breast cancer. We modified a previously published model for women at average risk for breast cancer ([@bib44]; [@bib2]) to account for differences in age-specific incidence, test characteristics (i.e., sensitivity and specificity), and tumour characteristics that are specific to women at high risk of breast cancer ([@bib12]; [@bib24]). These risk-specific model inputs and assumptions are required to evaluate the health and economic impact of various screening strategies for this high-risk cohort. We considered 12 screening strategies encompassing different MRI screening intervals (annual *vs* biennial) and cessation age (50 *vs* 74) combined with screening mammography plus CBE at intervals of 2, 1, or 0.5 years, or none. We modelled the impact of different screening strategies on costs, survival (life-years), and quality-adjusted life-years (QALYs). Costs in our model captured the entire spectrum of breast cancer care, from breast cancer screening, work-up procedures due to either true- or false-positive examinations, to breast cancer treatments and end-of-life care ([Figure 1](#fig1){ref-type="fig"}). We utilised estimates from published randomised breast cancer screening trials and observational studies as model inputs.

The model outputs are the expected QALYs and the expected total costs (direct medical costs and indirect costs) per woman, each discounted at 3% annually beginning at age 30. Incremental cost-effectiveness ratios (ICERs) were used to compare the screening strategies under consideration ([@bib36]; [@bib22]). Following a standard stepwise approach of comparing multiple strategies in economic evaluation, we rank-ordered the screening strategies by costs in ascending order, and ruled out strategies that are more costly but less effective than an alternative by simple dominance. The ICERs, interpreted as the additional cost required to achieve an increase of one QALY, were calculated for the remaining strategies by dividing the difference in the expected cost by the difference in the expected QALYs compared with the next least-expensive strategy. Strategies with a higher ICER than the ICER in the subsequent pair of comparison were further excluded by extended dominance and the ICER was recalculated after their elimination at each step ([@bib22]).

Natural history model
---------------------

This section provides a brief description of the microsimulation model. Detailed information can be found in our previously published studies ([@bib44]; [@bib45]; [@bib2]). We generated a birth cohort of 500 000 women by Monte Carlo simulation, where each woman\'s natural history was simulated independently. For women who develop breast cancer according to their age-specific incidence, we generated their natural histories of the disease over time. We assumed four states of the progressive disease in the natural history model ([@bib32]): disease-free or asymptomatic, detectable preclinical, clinical, and death. For women with breast cancer, their ages of death were modelled based on age and tumour characteristics at detection, and competing risks.

We calculated age-specific incidence rates for the 25% lifetime risk cohort by increasing the age-dependent hazard rates for the general population (13% lifetime risk) by a factor independent of age. The ages at onset of preclinical disease are unobservable and were mathematically derived given age-specific incidence of clinical disease and the postulated preclinical sojourn time distribution ([@bib33]). A random preclinical sojourn time was generated for each woman depending on her age at onset of preclinical disease, using the commonly used exponential distribution with an age-dependent component where the mean sojourn time, *μ*, depends on age at onset of preclinical disease. Uncertainty was incorporated through an inverse gamma prior for *μ* with scale and shape parameters that match the estimated means and s.d. of 1.0 (0.7) years for women ⩽50 and 1.9 (0.4) years for women \>50 ([@bib12]). For our study cohort (i.e., women with 25% lifetime risk for breast cancer), the preclinical sojourn times are shorter than those used for the general population, reflecting faster tumour growth ([@bib52]). We predicted survival times after diagnosis using a Cox regression model including age, tumour characteristics at diagnosis, and treatment. Clinical parameters in our model are summarised in [Table 1](#tbl1){ref-type="table"}.

Screening impacts and diagnostic procedures
-------------------------------------------

The sensitivity and specificity of mammography and CBE differ between the general population and women with high risk for breast cancer. For high-risk women, sensitivities of mammography and CBE have been shown to be lower, while specificities have been shown to be higher for both screening modalities compared to those for average-risk women ([@bib24]). The lower sensitivities may be partially explained by the higher breast density commonly observed among high-risk women who receive screening at a younger age, which contributes to difficult interpretation of the examinations. Following [@bib24], we modelled age- and tumour-size-specific sensitivity ([@bib23]; [@bib56]) and age-specific specificity for mammography, and constant sensitivity and specificity for CBE ([@bib19]). We used tumour-size-specific sensitivity and a constant specificity of MRI from [@bib24], where the sensitivity of MRI is higher than that of mammography given the same tumour size. Uncertainty was accounted for by using a beta distribution for each parameter of sensitivity and specificity. A logit model was used to model the age or tumour-size dependencies. The resulting estimates are similar to the range of sensitivities found in recent publications ([@bib39]; [@bib21]). The overall sensitivity and false-positive rate associated with a screening strategy that consists of varying combinations of the three examinations were calculated assuming independence of the modalities given the tumour size ([@bib46]). Because sensitivity and specificity of screening mammography are tumour size and/or age dependent, we listed these input parameters as ranges in [Table 1](#tbl1){ref-type="table"}; all other parameters are presented as average values.

We used diagnostic mammography as the form of initial work-up for positive or abnormal findings from screening examinations, with sensitivity and specificity estimated from the [@bib30]. A biopsy was used to confirm the disease after a positive finding from the initial work-up. If a woman has a symptomatically detected tumour, her disease status would also be confirmed with both a diagnostic mammography and a breast biopsy. Women in the preclinical state who are never diagnosed with breast cancer were assumed to die due to other causes. For women receiving a false-positive mammography, a follow-up mammography is provided 6 months after the last mammography, as in conventional breast cancer screening practice in the United States.

Simulation of survival and QALY following treatment
---------------------------------------------------

Tumour characteristics at diagnosis determined the type of treatment patients received in our model ([@bib31]). We predicted the number of nodes at diagnosis using a Poisson linear model given age and tumour size based on Surveillance, Epidemiology, and End Results (SEER) registry data ([@bib38]). We simulated ER status independently, assuming 70% of diagnosed cases to be ER positive ([@bib20]).

We determined the stage of disease using the tumour--node--metastasis staging system ([@bib48]) given tumour size and the predicted number of nodes. Given disease stage at diagnosis, patients received breast conserving surgery or mastectomy with or without radiation according to recent studies of breast cancer treatment patterns ([@bib6]; [@bib43]). The treatments of tamoxifen, chemotherapy, or a combination were based on dissemination patterns observed in the USA; the pattern varied by age, stage of disease, and ER status at diagnosis ([@bib28]). We obtained the treatment pattern of trastuzumab among chemotherapy users from a recent analysis of SEER-Medicare database ([@bib11]).

Covariate coefficients for age, primary tumour size, and number of nodes at diagnosis in the Cox regression used for the baseline predictive survival model were estimated based on a combined analysis of four Cancer and Leukemia Group B trials ([@bib58]; [@bib57]; [@bib35]; [@bib33]). We then used the hazard reductions to model the treatment effects of tamoxifen for ER-positive patients, chemotherapy and additional trastuzumab for HER2-positive patients on survival ([@bib28]; [@bib16]). If a woman\'s estimated breast cancer survival time was shorter than her simulated natural lifetime according to actuarial tables for the 1960 birth cohort from the U.S. Census Bureau, she would be assumed to have died of breast cancer; otherwise she would die from a competing cause.

To estimate QALY, we incorporated health utilities associated with the negative effects of breast cancer treatments (i.e., surgery, radiation, chemotherapy, and hormonal therapy) and terminal disease stage ([@bib51]). Utilities for the terminal stage of life associated with causes other than breast cancer were estimated using a weighted average of quality-of-life weights for the top three causes of death in women in the United States ([@bib9]) ([Table 2](#tbl2){ref-type="table"}). These utility values were weighted using the duration of the respective treatment or disease stage, to calculate QALY for each woman.

Costs
-----

In our model, costs captured the entire spectrum of breast cancer care. [Table 3](#tbl3){ref-type="table"} summarises the unit cost of health care resources incorporated in our estimation of direct medical costs, including screening mammography, CBE, MRI, diagnostic mammography, as well as biopsy and treatments ([@bib37]; [@bib59]; [@bib3]). For the treatment of breast cancer, we included costs by treatment phase (initial, continuing, and terminal) and cancer stage (local, regional, and distant) ([@bib59]; [@bib40]). In addition, we added costs associated with 5-year prescriptions of tamoxifen for women who are ER positive ([@bib3]) and trastuzumab costs for women who are HER2 positive ([@bib47]). Indirect costs from lost productivity for women who die prematurely from breast cancer (i.e., mortality costs resulting from lost wages) were estimated using age-specific wage rates for female workers in the labour market of the United States ([@bib17]). All costs were normalised to 2012 US dollars using the medical care component of the consumer price index ([@bib8]).

Sensitivity analysis
--------------------

We conducted sensitivity analyses to assess the robustness of our conclusions against key assumptions regarding the modelling parameters, such as changes in the lifetime risk (increase to 50% and 75%) and cost of MRI. Because of the high cost of MRI, a natural question that arises is whether reducing the cost of MRI would alter the cost-effectiveness of screening strategies involving MRI. Thus, we reduced the cost of MRI by 50% and 70%, which reduces the MRI cost from seven times to just over twice the cost of mammography, respectively.

Results
=======

[Table 4](#tbl4){ref-type="table"} shows the 12 screening strategies with various combinations of MRI and mammography plus CBE for women between ages 30 and 74, and who have a 25% lifetime risk of breast cancer at birth. MRI, at either an annual or biennial frequency, is included in every strategy, since our goal is to compare alternative approaches to timing MRIs and combining them with other screening modalities. The tradeoff plot for the 25% lifetime risk cohort is provided in [Figure 2](#fig2){ref-type="fig"}, which corresponds to [Table 4](#tbl4){ref-type="table"}. The dominated strategies are those that lie above the efficiency frontier. After excluding strategies that were dominated or extendedly dominated, four strategies remained in the cost-effectiveness comparison: strategy A that gives only MRI every 2 years, strategy B that staggers MRI and mammography+CBE every year and strategies F and L, which give mammography and CBE every 6 months with MRI every other year (strategy F) or MRI every year (strategy L). Compared to strategy A, the cheapest strategy, strategy B gained 0.0233 QALYs (∼8.5 quality-adjusted days) costing \$58 400 per QALY gained. Strategy F gained 0.0204 QALYs (\<8 quality-adjusted days) compared to strategy B, resulting in an ICER of \$323 700 per QALY. Finally, strategy L gained 0.0009 QALY (less than one quality-adjusted day) compared to strategy F, costing over an additional \$8.8 million per QALY. Therefore, if one has to adopt the ICER threshold of \$100 000/QALY, frequently chosen in recent literature ([@bib53]), the recommended strategy would be to stagger MRI and mammography plus CBE every year (i.e., strategy B).

Sensitivity analysis
--------------------

We explored six scenarios in our sensitivity analyses, including cohorts at increased lifetime risk (50% and 75%) and cost reductions of MRI (50% and 70% reduction) in the two high-risk cohorts: those with 25% *vs* 50% lifetime risk ([Table 5](#tbl5){ref-type="table"} and [Figures 3A--F](#fig3){ref-type="fig"}). With biennial MRI alone (strategy A) as our base of comparison (i.e., the lowest-cost strategy), strategy B remained the recommended strategy after reducing the cost of MRI by 50% or 70% for the cohort of women with 25% lifetime risk. As the lifetime risk increased to 50%, strategy B was highly cost-effective when compared to strategy A, yielding ICER ∼\$21 000/QALY with current MRI cost and ∼\$26 000/QALY with 50% reduction in MRI cost. When MRI cost was reduced by 70% for lifetime risk of 50% or higher, strategy J (i.e., staggering MRI and mammography+CBE every 6 months) became the recommended strategy from our cost-effectiveness analysis. When the lifetime risk of breast cancer was increased to 75%, the recommended strategy became biennial MRI combined with mammography+CBE every 6 months (i.e., strategy F).

Discussion
==========

Magnetic resonance imaging screening, because of its higher sensitivity compared to mammography, is commonly considered for women at high risk for breast cancer in the United States and many European countries. Although it may be beneficial to give high-risk women routine MRI examinations in addition to their regular mammography and CBE examinations, the high cost of MRI, combined with its lower specificity, raise the question of the optimal use of MRI in breast cancer screening programmes targeted at high-risk women. We employed a microsimulation model to answer this question.

Our analysis indicates that if MRI were to be integrated into the screening programmes for high-risk women, it would have to be combined with mammography plus CBE either concurrently or sequentially (i.e., staggered). Among all the screening strategies and scenarios of sensitivity analysis explored in our study, none supported the use of MRI as the sole screening modality for these women. In most cases, the strategy recommended from our cost-effectiveness analysis was to stagger MRI and mammography plus CBE every year (i.e., strategy B), although we found that at the current cost of MRI, a more frequent schedule of mammography plus CBE (combined with biennial MRI; i.e., strategy F) was cost-effective for women with a 75% or higher lifetime risk of breast cancer. We also found that if the MRI cost was substantially reduced (⩾70%), annual MRI staggered by annual mammography+CBE with 6 months interval in between (i.e., strategy J) was cost-effective for women with lifetime risk of 50% or greater. In the context of ACS guidelines for MRI screening in breast cancer, strategy J is especially interesting because the guidelines do not provide specific instructions on how to integrate MRI into mammography screening, such a strategy, which staggers the screening modalities every 6 months, is suggested as one possibility ([@bib42]). The potential advantage of this strategy is that it may reduce the rate of interval cancers by offering alternate screening every 6 months, affording earlier detection of more treatable tumours. However, based on our analysis, this strategy is only justified when there is a substantial reduction in MRI cost (⩾70%) compared to current cost and the lifetime risk of breast cancer was 50% or greater.

In contrast to previous studies that focused on *BRCA1/2* mutation carriers, our study focuses on a more general high-risk population of patients with a 25% or greater lifetime risk of developing breast cancer, which makes our study more applicable to provide screening recommendations to the general high-risk population. Restricting cost-effectiveness analysis to genetically susceptible women offers limited information to decision makers who are making policy recommendations for all high-risk women because breast cancer incidence in *BRCA1/2* mutation carriers is just ∼4% per annum in the age group of 40--49 years ([@bib5]). In addition, ongoing efforts have been made to improve existing prediction models for women at high risk using risk factors other than *BRCA* mutational status that can be obtained during routine screening examinations ([@bib7]; [@bib15]). All of this evidence supports the importance of assessing the cost-effectiveness of MRI in a broader group of patients than *BRCA1/2* mutation carriers.

Besides expanding our study beyond women with *BRCA1/2* mutation carriers, our study differs from prior cost-effectiveness analyses of MRI in which we include CBE as a part of the screening programmes under examination since CBE is commonly used in combination with mammography in screening practice. Our study is also unique in that it examines a more comprehensive list of screening strategies in the context of integrating MRI to existing screening programmes and incorporates detailed modelling of disease progression without assuming a screening benefit on survival. Instead, the potential survival benefit is reflected via stage shift at diagnosis given each individual\'s nodal status, tumour size, and sojourn time distribution. We also model the distribution of treatment according to simulated patient characteristics and treatment patterns reported from real-world data.

Despite the differences in risk profiles and modelling approaches among the studies, there is agreement that the use of MRI annually is unlikely to be cost-effective for the general high-risk cohort, but more likely to be cost-effective for certain high-risk subgroups such as those with \>45% lifetime risk of developing breast cancer, *BRCA1/2* mutation carriers, or very specifically selected age groups such as ages 35--54 ([@bib37]; [@bib29]; [@bib41]). Building upon previous findings that adding MRI to mammography and CBE may be cost-effective for high-risk women, our study explored the optimal way of integrating MRI into current practice in this cohort of women. We asked if MRI has to be integrated into the screening programmes for high-risk women and if at a minimum we are to offer MRI alone every other year, are other strategies with more frequent use of MRI and/or mammography+CBE more cost-effective than this lowest-cost strategy? Results of our analyses suggest that, for the women at 20--25% lifetime risk considered in the ACS guidelines, the current test characteristics and cost structure of MRI do not justify more frequent use of MRI other than the strategy that staggers MRI and mammography plus CBE every year.

Interestingly, the same conclusion was reached in a recent cost-effectiveness analysis from authors in the Netherlands that focused on women with familial risk for breast cancer ([@bib41]), defined as women with a lifetime risk between 15% and 50% in their model -- a range in line with the 25% lifetime risk in our base case analysis. However, this similarity needs to be interpreted with caution because of the difference in the comparators that formed the basis of the comparison, as well as difference in cost structure between countries. Specifically, the basis of comparison in [@bib41] was biennial mammography screening from age 50 to 75 years, which is the current protocol of the Dutch nationwide breast cancer screening programme, whereas our finding was based on the comparison to MRI alone every other year. In addition, the 'staggering\' strategy that was found to be cost-effective in their study only applied to women between 35 and 50 years of age (women were reverted back to biennial mammography after 50 years), while our model applied the 'staggering\' strategy to high-risk women between age 30 and 74 years. Furthermore, the cost of MRI was set to be much lower in the Netherlands than in the USA (\$485 *vs* \$728). All these considerations make it difficult to directly compare our study with [@bib41].

This study has several limitations. First, we do not model the survival outcomes associated with all recent therapeutic innovations, such as third-generation endocrine therapies, and we assume full compliance in terms of screening schedule. We did, however, incorporated the survival benefit according to recent treatment patterns for chemotherapies including trastuzumab, and the corresponding costs in our model. Second, the physical and emotional effects arising from either screening or from unnecessary procedures following false positives were not accounted for. However, because health utility decrements associated with these events often apply to a relative short time interval, these factors are unlikely to bias our finding in favour of any particular screening strategy and our ranking of strategies is likely to be robust. Third, overdiagnosis was not assessed in this study. By expanding our model to include non-invasive DCIS, we may quantify overdiagnosis resulting from screening programmes in a future study. Lastly, while clinical trials for assessing MRI in a high-risk group for breast cancer are currently underway ([@bib13]), there are no large randomised, controlled clinical trials that have been completed assessing the use of MRI as an additional screening modality for healthy women at high-risk for breast cancer. We thus relied on information available in the literature for our data inputs and models. As new information becomes available in the future, we can update our input parameters in the model accordingly.

Despite these limitations, our study provides evidence that the cost-effectiveness of adding routine MRI to mammography and CBE screening in women with increased risk for breast cancer will depend on the level of lifetime risk of the woman, the cost of MRI, as well as how often and in what combination MRI is implemented. Although the ACS recommendations are not explicit on how MRI should be incorporated into current practice, our findings suggests that staggering MRI with mammography/CBE with 1-year interval in between is likely to be a cost-effective screening strategy for women with a higher risk of breast cancer. From a societal perspective, the high costs associated with the low specificity of MRI are currently limiting factors for the annual schedule of MRI recommended by the ACS.
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![**Model structure for evaluating costs of screening, work-up, biopsy, and treatment for breast cancer.** '\$\' represents accrual of costs, and '+\' or '−\' represents a positive or negative test result. Abbreviations: MM=mammography; CBE=clinical breast examination; MRI=magnetic resonance imaging; BC=breast cancer.](bjc2014458f1){#fig1}

![**Tradeoff plot for the 25% lifetime risk cohort.** x-Axis is mean quality-adjusted life-years. y-Axis is mean total cost in 2012 US dollars. Dominated strategies lie above the cost-effectiveness frontier connecting the non-dominated alternatives.](bjc2014458f2){#fig2}

![**Tradeoff plots for six scenarios of sensitivity analyses.** (**A**) 25% LR and 50% reduction of MRI cost; (**B**) 25% LR and 70% reduction of MRI cost; (**C**) 50% LR and current MRI cost; (**D**) 50% LR and 50% reduction of MRI cost; (**E**) 50% LR and 70% reduction of MRI cost; and (**F**) 75% LR and current MRI cost. x-Axis is mean quality-adjusted life-years. y-Axis is mean total cost in 2012 US dollars. Dominated strategies lie above the cost-effectiveness frontier connecting the non-dominated alternatives. Abbreviation: LR=lifetime risk.](bjc2014458f3){#fig3}

###### Model inputs

                                                    **Range** **of values or constant**   **Reference**        
  ------------------------------------------------- ------------------------------------- -------------------- ------------------------------
  Age-specific incidence                            30⩽age\<50                            50⩽age\<90            
   25% Lifetime risk cohort                         0.06--0.26%                           0.32--0.74%           
  Sojourn time (mean (s.d.))                        age⩽50: 1.0 (0.7)                     age\>50: 1.9 (0.4)   [@bib12]
  MM sensitivity (age- and tumour size-dependent)   30⩽ age\<50                           50⩽age \<90          [@bib24]; [@bib39]; [@bib21]
   Tumour size=1 cm                                 0.307--0.491                          0.501--0.832          
   Tumour size=0.05 cm                              0.034--0.071                          0.074--0.283          
  MM specificity (age dependent)                    0.922--0.967                          0.968--0.995         [@bib24]
  CBE sensitivity                                   0.178                                                      [@bib24]
  CBE specificity                                   0.981                                                      [@bib24]
  MRI sensitivity (tumour size-dependent)                                                                      [@bib24]
   Tumour size=1 cm                                 0.710                                                       
   Tumour size=0.05 cm                              0.250                                                       
  MRI specificity                                   0.900                                                      [@bib24]; [@bib19]
  Diagnostic MM sensitivity                         0.880                                                      [@bib30]
  Diagnostic MM specificity                         0.900                                                       

Abbreviations: CBE=clinical breast examination; MM=mammography; MRI=magnetic resonance imaging. Random variation is added using a beta distribution for all sensitivity and specificity estimates. See description under Materials and Methods.

###### Health utility used in the simulation analysis

  **Intervention**                                    **Health utility**   **Duration of utility reduction**
  --------------------------------------------------- -------------------- -----------------------------------
  Breast surgery                                      0.87                 3 Months
  Radiation                                           0.80                 3 Months
  Chemotherapy                                        0.74                 1 Year
  Tamoxifen                                           0.99                 5 Years
  Terminal stage (breast cancer)                      0.29                 Last 3 months
  Terminal stage (other[a](#t2-fn1){ref-type="fn"})   0.375                Last 3 months

Estimated using a weighted average of weights for heart disease, cerebrovascular disease, and lung cancer in women.

###### Direct costs due to breast cancer screening, diagnosis (work-up and biopsy), and treatment (year 2012 dollars)

  **Cost components**                                                                                                                                                                                                 **Cost (\$)**       
  --------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- -------- --------------- ---------
  **Screening-related costs**                                                                                                                                                                                                        
   Mammography (bilateral)[a](#t3-fn2){ref-type="fn"}                                                                                                                                                                      142            
   Clinical breast examination[a](#t3-fn2){ref-type="fn"}                                                                                                                                                                  38             
   Magnetic resonance imaging[a](#t3-fn2){ref-type="fn"}                                                                                                                                                                   728            
   Diagnostic mammography (unilateral)[a](#t3-fn2){ref-type="fn"}                                                                                                                                                          171            
   Breast biopsy[a](#t3-fn2){ref-type="fn"}^,^[b](#t3-fn3){ref-type="fn"}                                                                                                                                                  656            
  **Treatment-related costs**                                                                                                                                                                                                        
   Tamoxifen/5 years[c](#t3-fn4){ref-type="fn"}                                                                                                                                                                           1281            
  Trastuzumab as adjuvant therapy/year[d](#t3-fn5){ref-type="fn"}                                                                                                                                                        60 087           
  Trastuzumab for metastatic BC[d](#t3-fn5){ref-type="fn"}^,^[e](#t3-fn6){ref-type="fn"} Annual costs by phase and stage[f](#t3-fn7){ref-type="fn"}                                                                      34 692           
                                                                                                                                                      Treatment phase (annual)[f](#t3-fn7){ref-type="fn"}    Local      Regional      Distant
                                                                                                                                                      Initial                                                13 057      24 685       38 125
                                                                                                                                                      Continuing[g](#t3-fn8){ref-type="fn"}                   1607        1607         1607
                                                                                                                                                      Terminal                                               35 340      41 831       58 673
  Monthly terminal phase costs (non-BC)[h](#t3-fn9){ref-type="fn"}                                                                                                                                                        4008            

Abbreviation: BC=breast cancer. The initial phase of care includes any adjuvant chemotherapy.

[@bib10].

[@bib37].

[@bib3].

Calculated based on the dosage for an average patient who is 170 cm tall and weighs 70 kg (i.e., body surface area=1.8 m^2^) and using the average sales price plus 6% mark-up initial dose of 4 mg kg^−1^ over 90 min i.v. infusion, then 2 mg kg^−1^ over 30 min i.v. infusion weekly for 52 weeks for adjuvant breast cancer and 7.4 months for metastatic breast cancer.

[@bib47].

[@bib59].

The original article did not report continuing phase costs by stage, we assumed the annual costs of continuing phase costs did not differ by cancer stages.

[@bib40].

###### Results of cost-effectiveness analysis in a 25% lifetime risk cohort

  **Strategy**   **MM intv(age)**         **CBE intv(age)**        **MRI intv(age)**        **Total cost (\$)**   **QALYs (years)**    **Increm QALYs gained**   **ICER**
  -------------- ------------------------ ------------------------ ------------------------ --------------------- ------------------- ------------------------- -----------
  A                                                                2 (30--74)               36 500                53.5215                        ---                ---
  B              2 (30--74)               2 (30--74)               2 (31--74)               37 900                53.5448                      0.0233             58 400
  C              1 (30--74)               1 (30--74)               2 (30--74)               40 600                53.5464                        ---                ---
  D              1 (30--74)               1 (30--74)               1 (30--50)               43 300                53.5490                        ---                ---
  E                                                                1 (30--74)               44 200                53.5455                        ---                ---
  F              0.5 (30--74)             0.5 (30--74)             2 (30--74)               44 700                53.5659                      0.0204             323 700
  G              1 (30--50), 2 (51--74)   1 (30--50), 2 (51--74)   1 (30--50), 2 (51--74)   45 500                53.5407                        ---                ---
  H              1 (30--74)               1 (30--74)               1 (30--50), 2 (51--74)   46 200                53.5472                        ---                ---
  I              2 (30--74)               2 (30--74)               1 (30--74)               46 600                53.5480                        ---                ---
  J              1 (30--74)               1 (30--74)               1 (30.5--74)             48 100                53.5662                        ---                ---
  K              1 (30--74)               1 (30--74)               1 (30--74)               48 900                53.5510                        ---                ---
  L              0.5 (30--74)             0.5 (30--74)             1 (30--74)               53 000                53.5668                      0.0009            8 833 800

Abbreviations: age=age range; CBE=clinical breast examination; ICER=incremental cost-effectiveness ratio (incremental cost/incremental QALYs gained compared to next least-expensive strategy); increm=incremental; intv=time interval between examinations (in years); MM=mammography; MRI=magnetic resonance imaging; QALYs=mean total expected quality-adjusted life-years per woman. Total cost is the mean total cost per woman in the complete cohort, rounded to the nearest \$100. Costs and QALYs are discounted at 3%. Strategies that are dominated or eliminated through extended dominance are indicated with '---\'.

###### Results of sensitivity analyses

                                       **Strategy**[a](#t5-fn2){ref-type="fn"}   **Total cost (\$)**  **QALYs (years)**   **Increm QALYs gained**                          **ICER**
  ----------------------------------- ----------------------------------------- --------------------- ------------------- ----------------------------------- -----------------------------------
  Base case (25% LR)                                      B                            37 900         53.5448             0.0232[b](#t5-fn3){ref-type="fn"}    58 400[b](#t5-fn3){ref-type="fn"}
  25% LR, 50% reduction in MRI cost                       B                            33 900         53.5448             0.0232[b](#t5-fn3){ref-type="fn"}    67 400[b](#t5-fn3){ref-type="fn"}
  25% LR, 70% reduction in MRI cost                       B                            32 300         53.5448             0.0232[b](#t5-fn3){ref-type="fn"}    71 000[b](#t5-fn3){ref-type="fn"}
  50% LR                                                  B                            55 300         53.2086             0.0412[b](#t5-fn3){ref-type="fn"}    20 700[b](#t5-fn3){ref-type="fn"}
  50% LR, 50% reduction in MRI cost                       B                            51 500         53.2086             0.0412[b](#t5-fn3){ref-type="fn"}    25 700[b](#t5-fn3){ref-type="fn"}
  50% LR, 70% reduction in MRI cost                       J                            53 500         53.2531             0.0392[c](#t5-fn4){ref-type="fn"}    84 400[c](#t5-fn4){ref-type="fn"}
  75% LR                                                  F                            79 900         52.8321             0.0749[d](#t5-fn5){ref-type="fn"}    62 800[d](#t5-fn5){ref-type="fn"}

Abbreviations: ICER=incremental cost-effectiveness ratio (incremental cost/incremental QALYs gained compared to next least-expensive strategy); increm=incremental; LR=lifetime risk; MRI=magnetic resonance imaging; QALYs=mean total expected quality-adjusted life-years per woman. Total cost is the mean total cost per woman in the complete cohort, rounded to the nearest \$100. Strategies listed are those with the lowest ICER compared to the cheapest strategy (strategy A) for each of the investigated scenarios.

Recommended strategy based on ICER threshold of \$100 000/QALY.

Compared to strategy A.

Compared to strategy E.

Compared to strategy B.
